TITLE

Medication Adherence Among Community-Dwelling Patients With Heart Failure

AUTHOR(S)
Dunlay, Shannon M.; Eveleth, Jessica M.; Shah, Nilay D.; McNallan, Sheila M.; Roger, Véronique L.
PUB. DATE
April 2011
SOURCE
Mayo Clinic Proceedings;Apr2011, Vol. 86 Issue 4, p273
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine medication use and adherence among community-dwelling patients with heart failure (HF). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with HF were recruited from October 10, 2007, through February 25, 2009. Pharmacy records were obtained for the 6 months after enrollment. Medication adherence was measured by the proportion of days covered (PDC). A PDC of less than 80% was classified as poor adherence. Factors associated with medication adherence were investigated. RESULTS: Among the 209 study patients with HF, 123 (59%) were male, and the mean ± SD age was 73.7±13.5 years. The median (interquartile range) number of unique medications flied during the 6-month study period was 11. (8-17). Patients with a documented medication allergy were excluded from eligibility for medication use within that medication class. Most patients received conventional HF therapy: 70% (147/209) were treated with β-blockers and 75% (149/200) with anglotensin-converting enzyme inhibitors or anglotensin II receptor blockers. Most patients (62%; 127/205) also took statins. After exclusion of patients with missing dosage information, the proportion of those with poor adherence was 19% (27/140), 19% (28/144), and 13% (16/121) for β-blockers, anglotensin-converting enzyme inhibitors or anglotensin II receptor blockers, and statins, respectively. Self-reported data indicated that those with poor adherence experienced more cost-related medication issues. For example, those who adhered poorly to statin therapy more frequently reported stopping a prescription because of cost than those with good adherence (46% vs 6%; P<.001), skipping doses to save money (23% vs 3%; P=.03), and not filling a new prescription because of cost (46% vs 6%; P<.001). CONCLUSION: Community-dwelling patients with HF take a large number of medications. Medication adherence was suboptimal in many patients, often because of cost.
ACCESSION #
59803638

 

Related Articles

  • Statins Pentraxin 3 and Heart Failure: What is the link? Abou-Raya, A.; Abou-Raya, S.; Helmii, M. // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 1, p187 

    An abstract of the article "Statins Pentraxin 3 and Heart Failure: What is the link?," by A. Abou-Raya, S. Abou-Raya and M. Helmii is presented.

  • statins.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2197 

    A definition of the term "statins," which refers to any of the drugs from the class known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, is presented.

  • Use of n-of-1 trials to determine statin tolerability.  // Reactions Weekly;Apr2014, Vol. 1495 Issue 1, p4 

    The article presents the findings of a recent study that confirmed the feasibility and potential value of n-of-1 trials in providing a reliable means of assessing whether such symptoms are in fact attributable to the statin.

  • Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. Gastelurrutia, Paloma; Lupón, Josep; de Antonio, Marta; Urrutia, Agustin; Díez, Crisanto; Coll, Ramón; Altimir, Salvador; Bayes-Genis, Antoni // Mayo Clinic Proceedings;Jun2012, Vol. 87 Issue 6, p555 

    Objective: To assess the relationship between statins and prognosis in ischemic and nonischemic patients with heart failure (HF) in a real-life cohort followed up for a long period. Patients and Methods: This prospective study included 960 patients with HF with preserved or depressed left...

  • Call to boost statin therapy adherence.  // Independent Nurse;1/15/2010, p1 

    The article presents the conclusion of several reviewed studies of adherence to statin medication in clinical trials and in normal practice.

  • Statin Therapy: Not Just for Cholesterol Anymore? Luks, Andrew M. // Critical Care Alert;Dec2009, Vol. 17 Issue 9, p69 

    This retrospective cohort study demonstrated that statin use was associated with a reduction in mortality in patients with severe sepsis (APACHE II > 24), but had no effect on mortality in those with less severe disease.

  • Noncholesterol-Lowering Effects of Statins. Pierre-Paul, Daphne; Gahtan, Vivian // Vascular & Endovascular Surgery;Sep/Oct2003, Vol. 37 Issue 5, p301 

    Statins, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, inhibit the rate-limiting enzyme in cholesterol synthesis and lead to a significant reduction of plasma lipid concentrations. As a clear correlation exists between serum cholesterol and cardiovascular risk, statins...

  • Exploiting a Physiological Regulator to Improve the Efficacy and Safety of Statins. Gill, Saloni; Brown, Andrew J. // Cardiovascular Drugs & Therapy;Apr2011, Vol. 25 Issue 2, p183 

    A letter to the editor is presented about the use of a physiological regulator to enhance the safety and efficacy of statins.

  • When to take statins; Lovaza versus OTC fish oil supplements. DeDea, Larissa // JAAPA: Journal of the American Academy of Physician Assistants (;May2011, Vol. 24 Issue 5, p23 

    The article offers the author's insights on the proper administration of statins, and on the difference between Lovaza and over-the-counter (OTC) fish oil supplements. The author says that it is still unknown whether taking statins during evening to lower cholesterol can lead to better results...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics